Loading...

Dynavax Technologies Corporation

DVAX•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$15.50
$0.00(0.00%)
U.S. Market opens in NaNh NaNm

Dynavax Technologies Corporation (DVAX) Stock Overview

Explore Dynavax Technologies Corporation’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap1.8B
P/E Ratio-41.89
EPS (TTM)$-0.37
ROE-0.08%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 Months$12.82
1 Year Target$12.13

DVAX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Dynavax Technologies Corporation (DVAX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 46.77, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $12.13.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -41.89 and a market capitalization of 1.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
43.52%
6-Month Change
64.72%
Year-to-Date (YTD) Change
0.78%
1-Year Change
13.22%
3-Year Change
58.81%
5-Year Change
51.81%
All-Time (Max) Change
-83.51%

Contact Information

https://www.dynavax.com
510 848 5100
2100 Powell Street, EmeryVille, CA, 94608

Company Facts

4,050 Employees
IPO DateFeb 19, 2004
CountryUS

Frequently Asked Questions